Mahmut Altindal
Research Subjects
Mahmut Altindal has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Ercan Türkmen
Department of Nephrology, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey
2 shared publications - Aydın Deveci
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey
1 shared publication - Aysun Aybal Kutlugun
Department of Nephrology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
1 shared publication - Bulent Altun
Hacettepe University
1 shared publication Cetin Turgan
Department of Nephrology, Ankara, Turkey
1 shared publication- Ergün Arıkan
Department of Internal Medicine, University of Health Sciences, Prof. Dr. CemilTaşçıoğlu City Hospital, Istanbul, Turkey.
1 shared publication
Latest Publications
- 22 May 2026
- Published by Springer Nature in Acta Diabetologica
- Vol. 63 (8) , 1-8
Polycythemia due to SGLT-2 inhibitors: who is at risk?
Introduction Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are oral antidiabetic agents that have been increasingly used in recent years. One of their lesser-known adverse effects is polycythemia (erythrocytosis), for which data remain limited. In this study, we aimed to investigate the incidence of erythrocytosis associated with SGLT-2 inhibitor use and the risk factors influencing these changes. Methods All patients who initiated SGLT-2 inhibitor therapy in our clinic between January 2020 and January 2021 were retrospectively evaluated. Hb and Hct levels were monitored for a median of 16 months following treatment initiation. Results Polycythemia developed in 15.1% (n = 58) of the 385 patients included in the study. Male sex and smoking were identified as significant risk factors for erythrocytosis, whereas insulin use and iron deficiency were found to be protective factors. The mean increase in hemoglobin levels among all patients was 0.97 ± 0.94 g/dL. A negative correlation was observed between baseline Hb levels and the degree of Hb increase associated with SGLT-2 inhibitor use. Patients who were excluded from the study due to baseline polycythemia (n = 18) were evaluated separately, and no significant change in their Hb levels was detected during follow-up. Conclusions SGLT-2 inhibitors significantly increase Hb and Hct levels in all patients without polycythemia. In anemic individuals, SGLT-2 inhibitors appear to induce greater increases in Hb and Hct, suggesting a potential additional hematologic benefit in this subgroup. Moreover, SGLT-2 inhibitors have been shown to be safe in patients with pre-existing polycythemia.
- 22 May 2026
- Published by Springer Nature in Acta Diabetologica
- Vol. 63 (8) , 1-8
Polycythemia due to SGLT-2 inhibitors: who is at risk?
Introduction Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are oral antidiabetic agents that have been increasingly used in recent years. One of their lesser-known adverse effects is polycythemia (erythrocytosis), for which data remain limited. In this study, we aimed to investigate the incidence of erythrocytosis associated with SGLT-2 inhibitor use and the risk factors influencing these changes. Methods All patients who initiated SGLT-2 inhibitor therapy in our clinic between January 2020 and January 2021 were retrospectively evaluated. Hb and Hct levels were monitored for a median of 16 months following treatment initiation. Results Polycythemia developed in 15.1% (n = 58) of the 385 patients included in the study. Male sex and smoking were identified as significant risk factors for erythrocytosis, whereas insulin use and iron deficiency were found to be protective factors. The mean increase in hemoglobin levels among all patients was 0.97 ± 0.94 g/dL. A negative correlation was observed between baseline Hb levels and the degree of Hb increase associated with SGLT-2 inhibitor use. Patients who were excluded from the study due to baseline polycythemia (n = 18) were evaluated separately, and no significant change in their Hb levels was detected during follow-up. Conclusions SGLT-2 inhibitors significantly increase Hb and Hct levels in all patients without polycythemia. In anemic individuals, SGLT-2 inhibitors appear to induce greater increases in Hb and Hct, suggesting a potential additional hematologic benefit in this subgroup. Moreover, SGLT-2 inhibitors have been shown to be safe in patients with pre-existing polycythemia.
- Open Access
- 30 May 2022
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 5 (3) , 799-804
Predictors and outcome of hyponatremia in patients with COVID 19: a single-center experience
Introduction/Aim: Hyponatremia (serum sodium 0.001) were the independent predictors of hyponatremia at the time of admission. The median length of hospital stay (LOS) was longer in patients with hyponatremia than patients with normonatremia (10 days vs. 8 days, p < 0.001). In multivariate analysis, hyponatremia was significantly associated with ICU admission or the need for mechanical ventilation (adjusted OR, 1.72; 95% confidence interval [95% CI], 1.03 to 2.85; p = 0.036). The severity of pneumonia, hemoglobin and lactate dehydrogenase levels, neutrophil-to-lymphocyte ratio (NLR), and body temperature were also associated with ICU admission or the need for mechanical ventilation. The oxygen saturation, male sex, serum albumin, NLR, and the ICU admission but not the hyponatremia on admission were significantly related to mortality. Conclusion: Hyponatremia on admission, even when mild, predicts a worse outcome in COVID-19 patients, and it should be considered in risk stratification.
- 30 May 2022
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 5 (3) , 799-804
Open AccessPredictors and outcome of hyponatremia in patients with COVID 19: a single-center experience
Introduction/Aim: Hyponatremia (serum sodium 0.001) were the independent predictors of hyponatremia at the time of admission. The median length of hospital stay (LOS) was longer in patients with hyponatremia than patients with normonatremia (10 days vs. 8 days, p < 0.001). In multivariate analysis, hyponatremia was significantly associated with ICU admission or the need for mechanical ventilation (adjusted OR, 1.72; 95% confidence interval [95% CI], 1.03 to 2.85; p = 0.036). The severity of pneumonia, hemoglobin and lactate dehydrogenase levels, neutrophil-to-lymphocyte ratio (NLR), and body temperature were also associated with ICU admission or the need for mechanical ventilation. The oxygen saturation, male sex, serum albumin, NLR, and the ICU admission but not the hyponatremia on admission were significantly related to mortality. Conclusion: Hyponatremia on admission, even when mild, predicts a worse outcome in COVID-19 patients, and it should be considered in risk stratification.
- 10 February 2012
- Published by Taylor & Francis in Amyloid
- Vol. 19 (1) , 28-32
The relation between urinary angiotensinogen and proteinuria in renal AA amyloidosis patients
Objective: The aim of this study was to evaluate the relationship of local intrarenal renin angiotensin system (RAS) with proteinuria in patients with renal AA amyloidosis. Methods: Thirty-two patients with renal AA amyloidosis (19 male, mean age: 45 ± 13 years) and sixteen healthy controls (5 male, mean age: 32 ± 5 years) were included in this study. Spot urine samples were obtained to measure urinary angiotensinogen (AGT) using human AGT-ELISA, urinary creatinine and protein levels. Logarithmic transformations of urinary AGT-creatinine ratio log(UAGT/Ucre) and urinary protein-to-creatinine ratio (UPCR) were done to obtain the normal distributions of these parameters. Results: Log(UAGT/UCre) was significantly higher in patients compared with the controls (1.88 ± 0.92 µg/g vs. 1.25 ± 0.70 µg/g; p = 0.023). Importantly a significantly positive correlation was found between log(UAGT/Ucre) and logUPCR in patients (r = 0.595, p = 0.006). Conclusions: Urinary AGT levels are higher in renal AA amyloidosis patients than in controls. Also, there is a significant positive correlation between urinary AGT and proteinuria in renal AA amyloidosis.
- 10 February 2012
- Published by Taylor & Francis in Amyloid
- Vol. 19 (1) , 28-32
The relation between urinary angiotensinogen and proteinuria in renal AA amyloidosis patients
Objective: The aim of this study was to evaluate the relationship of local intrarenal renin angiotensin system (RAS) with proteinuria in patients with renal AA amyloidosis. Methods: Thirty-two patients with renal AA amyloidosis (19 male, mean age: 45 ± 13 years) and sixteen healthy controls (5 male, mean age: 32 ± 5 years) were included in this study. Spot urine samples were obtained to measure urinary angiotensinogen (AGT) using human AGT-ELISA, urinary creatinine and protein levels. Logarithmic transformations of urinary AGT-creatinine ratio log(UAGT/Ucre) and urinary protein-to-creatinine ratio (UPCR) were done to obtain the normal distributions of these parameters. Results: Log(UAGT/UCre) was significantly higher in patients compared with the controls (1.88 ± 0.92 µg/g vs. 1.25 ± 0.70 µg/g; p = 0.023). Importantly a significantly positive correlation was found between log(UAGT/Ucre) and logUPCR in patients (r = 0.595, p = 0.006). Conclusions: Urinary AGT levels are higher in renal AA amyloidosis patients than in controls. Also, there is a significant positive correlation between urinary AGT and proteinuria in renal AA amyloidosis.